Would you consider treatment with sacituzumab in triple negative metastatic breast cancer if there has been progression on irinotecan?
Given sacituzumab is an antibody drug conjugate of the active metabolite of irinotecan
Answer from: Medical Oncologist at Academic Institution
While I am not aware of any data on the efficacy of sacituzumab govitecan (SG) in such patients, not surprising since irinotecan is not commonly administered to such patients, I would not rule out a trial of this agent. We know that ado-trastuzumab emtansine can be effective in patients progressing ...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
I do not use irinotecan in TNBC.
Answer from: Medical Oncologist at Community Practice
I have not yet encountered this in practice as irinotecan isn’t a chemotherapy that is used very frequently in breast cancer. Although the payload is SN-38, with sacituzumab being targeted to the cell via Trop-2, I think it would be reasonable to try with a close follow-up although we do not h...
Answer from: Medical Oncologist at Academic Institution
Irinotecan is not a chemotherapy that most breast oncologists use so we don't have any data on this. I would likely still use Sacituzumab in this space.